10/80 237 -43d -59 d -48 d +8 d -31 -54 d [6.81] [4.59] [1.65] [1.27] [1.92] [5.54] Atorvastatin by dose -27 -36 -31 +7 -21 -34 10 mg 238 [6.77] [4.53] [1.63] [1.25] [1.93] [5.52] 20 mg 237 -32 -44 -37 +5 -25 -41 [6.86] [4.61] [1.67] [1.26] [1.96] [5.60] 40 mg 237 -36 -48 -40 +4 -24 -45 [6.85] [4.65] [1.64] [1.30] [1.82] [5.55] 80 mg 239 -40 -53 -44 +1 -32 -50 [6.89] [4.72] [1.67] [1.24] [1.87] [5.65] Mean percent change from baseline † Baseline units are mmol/L for all parameters except Apo B, which is in g/L ‡ a For triglycerides, median % change from baseline b Baseline - on no drug c p<0.05 for difference with atorvastatin d p<0.05 for difference with atorvastatin at mg doses of the simvastatin component In a multicenter, double-blind, 24-week, forced titration study, 788 patients with primary hypercholesterolaemia, who had not met their NCEP ATP III target LDL-C goal, were randomised to receive co-administered ezetimibe and simvastatin equivalent to VYTORIN (10/10 and 10/20) or atorvastatin 10 mg. For all three treatment groups, the dose of the statin was titrated at 6week intervals to 80 mg. At each pre-specified dose comparison, VYTORIN
10/80 237 -43d [6.81] -59 d [4.59] -48 d [1.65] +8 d [1.27] -31 [1.92] -54 d [5.54] Atorvastatin by dose 10 mg 238 -27 [6.77] -36 [4.53] -31 [1.63] +7 [1.25] -21 [1.93] -34 [5.52] 20 mg 237 -32 [6.86] -44 [4.61] -37 [1.67] +5 [1.26] -25 [1.96] -41 [5.60] 40 mg 237 -36 [6.85] -48 [4.65] -40 [1.64] +4 [1.30] -24 [1.82] -45 [5.55] 80 mg 239 -40 [6.89] -53 [4.72] -44 [1.67] +1 [1.24] -32 [1.87] -50 [5.65] † Mean percent change from baseline ‡ Baseline units are mmol/L for all parameters except Apo B, which is in g/L a For triglycerides, median % change from baseline b Baseline - on no drug c p<0.05 for difference with atorvastatin d p<0.05 for difference with atorvastatin at mg doses of the simvastatin component In a multicenter, double-blind, 24-week, forced titration study, 788 patients with primary hypercholesterolaemia, who had not met their NCEP ATP III target LDL-C goal, were randomised to receive co-administered ezetimibe and simvastatin equivalent to VYTORIN (10/10 and 10/20) or atorvastatin 10 mg. For all three treatment groups, the dose of the statin was titrated at 6week intervals to 80 mg. At each pre-specified dose comparison, VYTORIN
auspar-ezetimibe-130228-simvastatin-pi.docx